Targeting a specific RNA to treat aggressive prostate cancer
Official title: Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer
Funded at Duke University · NIH-10763875 · Data updated 2026-11-12
This study is looking at a specific RNA called SChLAP1 that is connected to tougher types of prostate cancer, and it's for anyone affected by this disease, as researchers want to find out how SChLAP1 makes the cancer harder to treat and spread, so they can come up with better ways to help patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | January 12, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $171,672 |
| NIH project number | 5R21CA277305-02 |
| Project ID | NIH-10763875 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with aggressive or metastatic prostate cancer who have not responded to standard therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not developed therapy resistance may not benefit from this research.
What this research studies
This research focuses on a long noncoding RNA called SChLAP1, which is linked to aggressive forms of prostate cancer. The study aims to understand how SChLAP1 contributes to therapy resistance and cancer spread, which are major challenges in treating prostate cancer. By investigating the molecular mechanisms of SChLAP1, researchers hope to develop new therapeutic strategies that can effectively target this RNA and improve patient outcomes. The approach includes analyzing the interactions of SChLAP1 with other cellular components to identify potential treatment pathways.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients with therapy-resistant prostate cancer, potentially improving survival rates.
How similar studies have gone: While targeting long noncoding RNAs is a relatively novel approach, preliminary studies have shown promise in similar contexts, indicating potential for success.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Hargrove, Amanda E — Duke University
- Study coordinator: Hargrove, Amanda E
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.